Eli Lilly's Zepbound Outperforms Wegovy in Weight Loss Trial, Boosting Stock

Eli Lilly's obesity drug Zepbound has demonstrated superior weight loss results compared to Novo Nordisk's Wegovy in a head-to-head clinical trial. Over 72 weeks, Zepbound users lost an average of 20.2% of their body weight, compared to 13.7% for Wegovy users. The trial, which involved 751 patients, highlights Zepbound's potential to dominate the weight loss drug market, projected to be worth $150 billion annually by the early 2030s. Both drugs are costly, around $1,000 per month, and face challenges with insurance coverage.